Open AccessThe Postprandial-to-Fasting Serum C-Peptide Ratio is a Predictor of Response to Basal Insulin-Supported Oral Antidiabetic Drug(s) Therapy: A Retrospective Analysis
Author(s) -
Panwei Mu,
Dezhao Liu,
Lin Ying,
Dong Liu,
Fan Zhang,
Yongjun Zhang,
Shuo Lin,
Linqin Wang,
Manman Wang,
Jiong Shu,
Longyi Zeng,
Yanming Chen
Publication year - 2018
Publication title -
diabetes therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.907
H-Index - 33
ISSN - 1869-6961
DOI - 10.1007/s13300-018-0404-6
Subject(s) - medicine , glycemic , postprandial , insulin , basal (medicine) , diabetes mellitus , c peptide , type 2 diabetes mellitus , basal insulin , drug , endocrinology , type 2 diabetes , gastroenterology , pharmacology
Basal insulin is widely recommended for the treatment of type 2 diabetes mellitus (T2DM) patients who are unable to achieve glycemic control with oral antidiabetic drug(s) (OADs). However, some patients are still unable to control their blood glucose levels even when on basal insulin-supported OAD(s) therapy (BOT). The aim of this study was to investigate the factor(s) predicting patient response to BOT.